Strategic partnerships There is an expanding distribution partnership with Medtronic to distribute the Argos Cardiac Output Monitor across Western Europe, signaling a channel-first opportunity to leverage established sales networks and accelerate market reach.

Clinical leadership Retia has a strong Clinical Advisory Board and notable clinician hires, presenting a compelling gateway to hospital procurement through key opinion leaders and credibility with surgical and ICU teams.

High-risk patient focus The Argos monitor targets high-risk surgical and critically ill patients, aligning with institutions aiming to reduce complication rates and length of stay, thereby supporting a value-based selling narrative to cardiothoracic and critical care departments.

FDA clearance momentum With FDA 510(k) clearance launched in 2018 and ongoing validation studies, there is a proven regulatory track record to reassure buyers about safety, efficacy, and continued product support.

Funding and growth Past Series B funding and steady revenue growth, including a recent strategic advisory hires, indicate financial stability and a scalable business model attractive to hospital systems seeking proven, vendor-backed solutions.